Salvage therapy of multiple myeloma: the new generation drugs.
about
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsA phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma.
P2860
Salvage therapy of multiple myeloma: the new generation drugs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Salvage therapy of multiple myeloma: the new generation drugs.
@en
type
label
Salvage therapy of multiple myeloma: the new generation drugs.
@en
prefLabel
Salvage therapy of multiple myeloma: the new generation drugs.
@en
P2093
P2860
P50
P356
P1476
Salvage therapy of multiple myeloma: the new generation drugs.
@en
P2093
Alessia La Fauci
Concetta Conticello
Cosimo Di Raimondo
Elena Schinocca
Nunziatina Laura Parrinello
P2860
P304
P356
10.1155/2014/456037
P407
P5008
P577
2014-05-19T00:00:00Z